In a Nutshell
Both stimulate growth hormone release, but through different receptors — and their regulatory histories differ materially.
Sermorelin is a GHRH analog. It acts on the GHRH receptor, the same one your body's own growth hormone-releasing hormone uses. It was previously FDA-approved as GEREF, and FDA formally determined those approvals were not withdrawn for safety or effectiveness reasons.
Ipamorelin is a ghrelin receptor agonist — a growth hormone secretagogue acting on a different receptor (GHS-R), the one ghrelin uses. It has never been FDA-approved.
The decisive difference is regulatory. Ipamorelin acetate is currently in FDA Category 2 — the agency's list of bulk substances that "may present significant safety risks" — under the 503B interim policy, and it also appears on the nominated-but-withdrawn list 1. FDA's public summary notes serious adverse events, including two deaths, in a 117-patient trial of intravenous ipamorelin following bowel surgery. FDA's detailed review reported serious-adverse-event rates of 17.9% with ipamorelin and 15.5% with placebo, and stated that it was unclear whether the deaths were related to ipamorelin.
The study does not establish either the safety or the danger of subcutaneous wellness use. FDA nevertheless treated those findings, together with the absence of adequate subcutaneous safety data, as grounds for concern.
Ipamorelin was also referred to FDA's advisory committee in 2024, where the committee voted against recommending it for the 503A Bulks List.
Side by Side
| Sermorelin | Ipamorelin | |
|---|---|---|
| Class | GHRH analog | Ghrelin receptor agonist (GHS) |
| Receptor | GHRH receptor | GHS-R (ghrelin receptor) |
| Size | 29 amino acids | 5 amino acids |
| Mechanism | Activates pituitary GHRH receptors to stimulate endogenous GH release | Mimics ghrelin's GH-releasing action |
| Effect on cortisol/prolactin | Minimal | Minimal — ipamorelin's main claimed advantage over older GHRPs |
| Effect on appetite | Minimal | May increase appetite (ghrelin pathway) |
| FDA approval history | Previously approved (GEREF, 1990 & 1997) | Never approved |
| Current FDA list status | Not on Category 2 or nominated-but-withdrawn lists | Category 2 (503B), and on nominated-but-withdrawn list |
| FDA-identified safety concerns | None published — not in Category 2 and no FDA safety-risk summary (long-term safety of chronic compounded adult use is nonetheless not established) | Concerns from an IV postoperative trial; causality for two deaths unclear, and subcutaneous safety data insufficient |
| Advisory committee outcome | Not reviewed | Voted against (2024) |
The Regulatory Difference in Detail
FDA's published tables list ipamorelin acetate in two places — which is unusual and worth understanding 1:
- Category 2 under the 503B interim policy — bulk substances FDA has identified as potentially presenting significant safety risks
- Nominated but withdrawn — the nomination was withdrawn by the nominator. This records procedural history; it is not a separate adverse safety finding, and should not be read as one
FDA's stated reasoning covers both a data gap and a specific signal: compounded ipamorelin "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities," it "contains unnatural amino acids, which add to the complexity of peptide characterization," and the literature identifies serious adverse events including two deaths in an intravenous postoperative trial — with FDA noting causality was unclear 1.
Two points of fairness. First, that fatal-adverse-event signal concerns intravenous administration for gastric motility — a different route and clinical context from subcutaneous use for body composition. FDA notes separately that it has not identified safety information for certain other injectable routes, and therefore "lacks sufficient information to know whether the drug would cause harm" via those 1. Second, none of this establishes that ipamorelin is dangerous as commonly used. It establishes that FDA has both a specific concern and a general absence of data.
Sermorelin carries neither designation. See Are Peptides Legal in the US? for the full framework.
What About CJC-1295 + Ipamorelin?
The most-searched form of this question involves the combination, since ipamorelin is usually marketed stacked with CJC-1295.
The logic behind pairing them is real: CJC-1295 is a GHRH analog (like sermorelin) and ipamorelin a ghrelin receptor agonist, so the combination pushes two different receptors — theoretically producing a larger release than either alone.
The regulatory position, however, does not improve. CJC-1295 also appears on FDA's nominated-but-withdrawn list, with FDA noting "serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction," and that available clinical data are limited 1.
So the combination pairs one substance with a documented cardiovascular signal and another with a documented fatal-adverse-event report in a different route — neither approved, both the subject of FDA concern. That the stack may produce a larger growth hormone release does not resolve the question of whether it should be used.
Is Ipamorelin More Effective?
Possibly — and that question is less useful than it appears.
Ipamorelin acts on a different receptor and, when combined with a GHRH analog, can produce greater growth hormone release than a GHRH analog alone. Advocates present this as a straightforward advantage.
Two problems with that framing. First, a larger hormone release is not automatically a better clinical outcome — the effects associated with growth hormone excess are dose-related, and the more moderate, pituitary-mediated response of a single GHRH analog is a design feature — though feedback does not guarantee levels stay within range. Second, the comparison has not been made in controlled human trials measuring outcomes that matter — body composition, sleep quality, functional change — rather than serum growth hormone levels. Effect on a biomarker is not the same as effect on a patient.
For a therapy where the regulatory position is unfavorable and the outcome evidence is absent, "may release more growth hormone" is a thin basis for choosing it.
Which Is Appropriate?
If a clinician is already considering a compounded growth hormone secretagogue for an individualized adult goal, sermorelin has the more favorable regulatory history — a documented prior approval, no Category 2 listing, and an FDA determination that its withdrawal was not for safety or effectiveness reasons. That is a reason to prefer it over ipamorelin or CJC-1295 if such a therapy is being used at all; it does not establish that it is clinically appropriate for those goals, where adult evidence remains limited.
Sermorelin's position is not the strongest of any growth hormone secretagogue — tesamorelin has the stronger formal status of a current FDA approval, albeit for a narrow indication. And absence from Category 2 is not an FDA conclusion that today's compounded sermorelin is safe, effective or appropriate for adult wellness use.
Neither has an FDA-approved label to quote from, so there is no formal contraindication list for either — and that absence is itself the point. Where a compounded preparation is being considered at all, a malignancy history, pregnancy or planned pregnancy, disordered glucose regulation, and pituitary or hypothalamic disease each call for individual specialist assessment against the specific preparation, rather than against a general rule.
Separately: competing under an anti-doping code prohibits growth hormone secretagogues regardless of prescription status. That is an eligibility question rather than a medical one.
Who Sermorelin Is Not For
Compounded sermorelin has no FDA-approved label, so there is no formal contraindication list to quote. Clinicians prescribing on this axis treat as absolute: a prior allergic reaction to sermorelin, particularly anaphylaxis; pregnancy, planned near-term pregnancy or breastfeeding; active malignancy; significant hypothalamic-pituitary structural disease or an intracranial lesion; and acute critical illness or recent major surgery.
Treated as relative — individual assessment rather than a blanket rule: cancer in remission, including at five years and handled with the treating oncologist; diabetes, prediabetes or insulin resistance; uncontrolled thyroid disease; and significant liver or kidney disease.
Separately: sermorelin is prohibited by the World Anti-Doping Agency, a disqualifier under any anti-doping code regardless of prescription status.
Full list and the monitoring that accompanies it: dosing and monitoring.
Red Flags
- A provider presenting ipamorelin or CJC-1295 as "FDA approved" — neither has ever been approved
- A provider unaware of ipamorelin's Category 2 designation — it is on FDA's published list
- Ipamorelin or CJC-1295 shipped direct for self-treatment with no prescriber or clinical pathway — typically research-grade, labeled not for human use
- Any growth hormone secretagogue used while competing under an anti-doping code
Get Started with JumpstartMD
Choosing between secretagogues is a smaller decision than most people expect. The larger one is whether the growth hormone axis is what is actually driving your symptoms.
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, delivered by licensed clinicians you see face-to-face — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning, repeated at visits. Fatigue, poor recovery and changing body composition frequently trace to thyroid function, iron status, testosterone, sleep quality or a training and nutrition gap, and treating the actual cause is the better-evidenced route than optimizing a pathway that was not the problem. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Sermorelin is supplied as a compounded preparation, not an FDA-approved finished drug: GEREF was historically approved for diagnostic use and pediatric growth hormone deficiency — not adult sleep, recovery, body-composition or healthy-aging goals — and controlled evidence for those adult outcomes remains limited.
Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Sermorelin: What It Is and How It Works — the main guide
- Sermorelin vs HGH — the other comparison worth understanding
- Are Peptides Legal in the US? — Category 2 and the bulks list explained
- Sermorelin Side Effects and Safety
- Peptide Therapy: What It Is and Who It's For
Frequently Asked Questions
Which is better, sermorelin or ipamorelin?
They act on different receptors, and no controlled human trial has compared them on outcomes that matter. What most clearly differs is the regulatory history: sermorelin was previously FDA-approved and FDA determined its withdrawal was not for safety or effectiveness reasons; ipamorelin has never been approved, sits in FDA Category 2 under the 503B interim policy, and was voted against by FDA's advisory committee in 2024.
Is ipamorelin FDA approved?
No, and its regulatory position is less favorable than that of most peptides discussed in this category. FDA lists ipamorelin acetate in Category 2 — substances that may present significant safety risks — under the 503B interim policy, and PCAC voted against recommending both forms for the 503A Bulks List on October 29, 2024. FDA's concerns include a 117-patient trial of intravenous ipamorelin after bowel surgery in which two deaths occurred, though FDA stated it was unclear whether they were related to ipamorelin, and serious-event rates were similar to placebo (17.9% versus 15.5%).
What is CJC-1295 ipamorelin used for?
The combination is marketed for growth hormone support, recovery and body composition, pairing a GHRH analog with a ghrelin receptor agonist to stimulate two receptors. Neither component is FDA-approved, and both appear on FDA's nominated-but-withdrawn list — CJC-1295 with noted adverse events including increased heart rate and systemic vasodilatory reaction.
Does ipamorelin increase appetite?
It may. Ipamorelin acts on the ghrelin receptor, and ghrelin is centrally involved in appetite signaling. Sermorelin, acting on the GHRH receptor, does not share this pathway — which matters if body composition is the goal.
Is sermorelin or ipamorelin better for weight loss?
Neither is a weight-loss treatment. They are marketed for body composition — used with the aim of preserving lean mass, an effect that has not been established in controlled adult studies — rather than for scale weight. If fat loss is the goal, the FDA-approved GLP-1 medications have substantially stronger evidence. See GLP-1 medications for weight loss.
Can you take sermorelin and ipamorelin together?
Combinations of GHRH analogs and ghrelin receptor agonists are marketed. The regulatory position of both components is the substantive objection: neither is FDA-approved, ipamorelin sits in Category 2 under the 503B interim policy, and FDA's advisory committee voted against both CJC-1295 and ipamorelin in 2024. Sermorelin has never been before that committee. Any such decision belongs with a prescribing clinician who has assessed you.
References
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, "Determination That GEREF (Sermorelin Acetate) Injection... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness," Federal Register, vol. 78, pp. 14095-14096, Mar. 4, 2013. [Online]. Available: https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, "Pharmacy Compounding Advisory Committee Meeting, October 29, 2024 — Minutes," pp. 7-8. [Online]. Available: https://www.fda.gov/media/185412/download (meeting page: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-29-2024-meeting-pharmacy-compounding-advisory-committee-10292024) [Accessed: Oct. 5, 2026]. ↩
- C. Dieguez, M. López, F. Casanueva, "Hypothalamic GHRH," Reviews in Endocrine and Metabolic Disorders, vol. 26, pp. 297-303, Jun. 2025, [Online]. Available: https://doi.org/10.1007/s11154-025-09951-y. PMID: 39913072. PMCID: PMC12137398. [Accessed: Jul. 26, 2026]. ↩
- D. E. Beck, W. B. Sweeney, M. D. McCarter, and the Ipamorelin 201 Study Group, "Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients," International Journal of Colorectal Disease, vol. 29, no. 12, pp. 1527-1534, Dec. 2014, [Online]. Available: https://doi.org/10.1007/s00384-014-2030-8. PMID: 25331030. ClinicalTrials.gov NCT00672074. [Accessed: Oct. 5, 2026]. ↩